Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA launches new priority review voucher program for select biopharmas
Eli Lilly
Biotech
Scholar Rock's SMA drug helps Zepbound patients retain muscle
Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound maintain muscle mass.
James Waldron
Jun 18, 2025 9:10am
Eli Lilly pays $1B upfront to buy gene editing partner Verve
Jun 17, 2025 4:35am
Lilly's amylin data impress with 11% weight loss, tolerability
Jun 16, 2025 4:55am
Novo plots ph. 3 trials for next-gen obesity asset amycretin
Jun 13, 2025 10:35am
Eli Lilly inks $650M Juvena pact to find muscle-boosting drugs
Jun 11, 2025 7:30am
Scorpion spinout Antares raises $177M for preclinical portfolio
Jun 10, 2025 10:07am